Dapagliflozin treatment and cardiovascular outcome in RBP4/TTRVal30Met (transthyretin cardiac amyloidosis) mice

ConclusionsDapagliflozin did not improve cardiovascular prognosis including the progression of heart failure, cardiac inflammation, and pathological changes in ATTR-CA mice compared with placebo. The results of this study were not in support of dapagliflozin's therapeutic effects for ATTR-CA. More pre-clinical and clinical researches to validate these findings and demonstrate the underlying mechanisms are still required.

Source: ESC Heart Failure - October 26, 2023 Category: Cardiology Authors: Zonglin Li, Fang Lv, Xin Wen, Chengcheng Guo, Li Li, Xiaoling Cai, Chu Lin, Mengqing Zhang, Wenjia Yang, Linong Ji Tags: Original Article Source Type: research